Melissa Calmann is an accomplished regulatory scientist specializing in biologics and cell and gene therapy. With extensive experience in global CMC regulatory affairs, they have held leadership positions at various companies, including BeOne Medicines and Johnson & Johnson. Melissa has a successful publication record and has developed regulatory strategies for drug applications worldwide. They currently lead the global regulatory CMC efforts for the Galapagos portfolio of cell therapy programs. Melissa earned a PhD in Biochemistry and Molecular Pharmacology from the University of Massachusetts Medical School.
This person is not in any teams
This person is not in any offices